The lung is one of the most common sites of metastases, with approximately 50% of patients with extrathoracic cancer exhibiting pulmonary metastases. Correct identification of the metastatic status of a lung lesion is vital to therapeutic planning and better prognosis. However, currently available diagnostic techniques, such as conventional radiography and low dose computed tomography (LDCT), may fail to identify metastatic lesions. Alternative techniques such as Raman spectroscopy (RS) are hence being extensively explored for correct diagnosis of metastasis. The current ex vivo study aims to evaluate the ability of a fiber optic-based Raman system to distinguish breast cancer metastasis in lung from primary breast and lung tumor in animal models. In this study, spectra were acquired from normal breast, primary breast tumor, normal lung, primary lung tumor, and breast cancer metastasis in lung tissues and analyzed using principal component analysis and principal component-linear discriminant analysis. Breast cancer metastasis in lung could be classified with 71% classification efficiency. Approximately 6% breast metastasis spectra were misclassified with breast tumor, probably due to the presence of breast cancer cells in metastasized lungs. Test prediction results show 64% correct prediction of breast metastasis, while 13% breast metastasis spectra were wrongly predicted as breast tumor, suggesting the possible influence of breast cancer cells. Thus, findings of this study, the first of such explorations, demonstrate the potential of RS in classifying breast metastasis in lungs from primary lung and primary breast tumor. Prospective evaluation on a larger cohort with better multivariate analysis, combined with LDCT and recently developed real-time in vivo probes, RS can play a significant role in nonsurgical screening of lesions, which can lead to individualized therapeutic regimes and improved prognoses.
Raman spectroscopy (RS) has been extensively explored as an alternative diagnostic tool for breast cancer. This can be attributed to its sensitivity to malignancy-associated biochemical changes. However, biochemical changes due to nonmalignant conditions like benign lesions, inflammatory diseases, aging, menstrual cycle, pregnancy, and lactation may act as confounding factors in diagnosis of breast cancer. Therefore, in this study, the efficacy of RS to classify pregnancy and lactation-associated changes as well as its effect on breast tumor diagnosis was evaluated. Since such studies are difficult in human subjects, a mouse model was used. Spectra were recorded transcutaneously from the breast region of six Swiss bare mice postmating, during pregnancy, and during lactation. Data were analyzed using multivariate statistical tool Principal Component–Linear Discriminant Analysis. Results suggest that RS can differentiate breasts of pregnant/lactating mice from those of normal mice, the classification efficiencies being 100%, 60%, and 88% for normal, pregnant, and lactating mice, respectively. Frank breast tumors could be classified with 97.5% efficiency, suggesting that these physiological changes do not affect the ability of RS to detect breast tumors.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.